腹腔内溶瘤病毒免疫治疗铂耐药或难治性卵巢癌的1b期研究
该开放标签1b期试验采用3+3剂量递增,评估腹腔内Olvi-Vec单药治疗铂耐药或难治性卵巢癌的安全性和疗效。
要点
- Olvi-Vec腹腔内给药在铂耐药/难治性卵巢癌中安全性可接受,无4级TRAE或治疗相关死亡。
- 客观缓解率9%(1/11),疾病稳定率64%(7/11),中位PFS 15.7周(95%CI: 5.7-34.5)。
- 观察到CD8+ T细胞瘤内浸润增加及外周血肿瘤特异性T细胞激活,提示免疫激活。
核心结论
- 腹腔内Olvi-Vec溶瘤病毒治疗在铂耐药或难治性卵巢癌患者中显示出良好的安全性、临床活性和免疫激活,值得进一步临床研究。
研究设计与样本
- 开放标签1b期试验,采用3+3剂量递增设计,Olvi-Vec腹腔内单药连续两天给药。
- 三个剂量队列:3×10^9 PFU/天(n=6)、1×10^10 PFU/天(n=5)、2.5×10^10 PFU/天(n=1),均连续两天给药。
主要发现
- 治疗相关不良事件包括1/2级恶心(n=6)、发热(n=6)、腹胀(n=5)和腹痛(n=4)。
- 未发生4级治疗相关不良事件,不良事件与剂量无关系,无归因于Olvi-Vec的死亡。
- 客观缓解率为9%(1/11),疾病稳定率为64%(7/11),疾病稳定≥15周者为46%(5/11)。
- 中位无进展生存期为15.7周(95%CI: 5.7-34.5),4例患者PFS延长(23.2、34.5、59.4+和70.8周)。
- 3例患者总生存期延长(1例死亡于33.6个月,2例分别带瘤生存54和59个月)。
临床怎么用
- 对于铂耐药或难治性卵巢癌,腹腔内Olvi-Vec单药治疗安全性可接受,可作为后续临床研究的候选方案。
- 治疗期间需关注恶心、发热、腹胀和腹痛等1/2级不良事件,无需因剂量关系调整剂量。
局限性
- 最高剂量队列仅纳入1例患者,剂量-效应关系评估不充分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objective was to assess safety and adverse events associated with intraperitoneal Olvi-Vec virotherapy in patients with platinum-resistant or refractory ovarian cancer (PRROC). Secondary objectives included objective response rate (ORR) per RECIST 1.1 and progression-free survival (PFS). METHODS: Olvi-Vec is a modified vaccinia virus that causes oncolysis and immune activation. An open-label phase 1b trial using a 3 + 3 dose escalation was conducted. Intraperitoneal Olvi-Vec was given as monotherapy in two consecutive daily doses. Translational analyses included anti-virus antibody levels, viral shedding, circulating tumor cells (CTCs) and T cells. RESULTS: Twelve patients (median age: 69 years, range: 45-77) with median 5 prior therapies (range: 2-10) and 2 prior platinum lines (range: 1-5) were enrolled. There were three dose level cohorts: 3 × 109 (n = 6), 1 × 1010 (n = 5), and 2.5 × 1010 (n = 1) plaque forming units (PFU)/day on two consecutive days. Treatment-related adverse events (TRAEs) included G1/G2 nausea (n = 6), fever (n = 6), abdominal distention (n = 5), and abdominal pain (n = 4). There were no Grade 4 TRAEs, no dose relationship to TRAEs, and no deaths attributed to Olvi-Vec. The ORR was 9% (1/11). Stable disease (SD) was 64% (7/11), and SD ≥15 weeks was 46% (5/11). Median PFS was 15.7 weeks (95%CI: 5.7-34.5), including extended PFS in four patients (23.2, 34.5, 59.4+ and 70.8 weeks). Three patients had extended overall survival (deceased 33.6 months, and alive with disease at 54 and 59 months). CTCs diminished in 6/8 (75%) baseline-positive patients. Immune activation was demonstrated from virus-enhanced tumor infiltration of CD8+ T-cells and activation of tumor-specific T-cells in peripheral blood. CONCLUSIONS: Oncolytic viral therapy with intraperitoneal Olvi-Vec showed promising safety, clinical activities, and immune activation in patients with PRROC, warranting further clinical investigation.
引用
- Manyam M, Stephens AJ, Kennard JA, et al. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2021. PMID: 34686353. doi:10.1016/j.ygyno.2021.10.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。